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Summary We examined the expression of pancreatic secretory trypsin inhibitor (PSTI) in colorectal cancer by
immunohistochemical staining using an anti-PSTI antiserum, an in situ hybridisation technique utilising
sulphonated PSTI cDNA probe, and a Northern blot hybridisation method, using a 32P-labelled PSTI cDNA
probe. Immunohistochemically, PSTI was detected in 80 of 95 (84%) colorectal cancer cases. Analyses with in
situ hybridisation as well as Northern blot hybridisation demonstrated PSTI mRNAs in immunohisto-
chemically positive cases, showing PSTI could be produced in colorectal cancerous cells. Histologically well or
moderately differentiated adenocarcinoma showed higher incidence of PSTI immunoreactivitity than the other
types. Furthermore, the intensity of the immunohistochemical staining for PSTI increased the more cases
advanced, particularly in regard to depth of invasion and tumour size. Thus, PSTI expression is widespread in
colorectal cancer, and occurs more commonly in advanced cases. Considering the suggestion that PSTI is a
growth-stimulating factor as an well as inhibitor to proteolytic proteinase, the present findings may indicate
that PSTI expressed in colorectal cancerous cells may play a role possibly closely associated with tumour
development.
Pancreatic secretory trypsin inhibitor (PSTI) consists of a
single polypeptide chain, and is known to be a specific tryp-
sin inhibitor in the pancreas. Its physiological role has been
considered to prevent the premature activation of trypsin in
the pancreatic acini and ducts (Kazal et al., 1948). However,
PSTI has also been demonstrated in various malignant cell
lines and tissues, including pancreatic cancer, lung cancer,
gynaecological cancer, and gastric cancer (Higashiyama et
al., 1990; Ogata, 1988; Ogawa et al., 1987; Tomita et al.,
1987; Ueda et al., 1989); the physiological role of PSTI in
neoplastic tissue remains unknown. Nevertheless, several
investigators have recently shown that PSTI may have func-
tions other than the inhibition of trypsin activity, such as
growth factor action (Niinobu et al., 1986; Ogawa et al.,
1985, 1987). In fact, we have shown that the expression of
PSTI in gastric cancer may possibly be associated with
tumour growth and progression (Higashiyama et al., 1990).
Although it has been reported that PSTI may be expressed
in villous adenoma of the colon (Bohe et al., 1986; Tomita et
al., 1987), there has been-u-study of the expression of PSTI
in colorectal cancer, except for the preliminary report
(Ogawa et al., 1987). In the present study, we demonstrate
that colorectal cancer may also express PSTI, not only by
immunohistochemical analysis for detection at the product
level but also by in situ hybridisation and Northern blot
hybridisation for detection at the transcriptional level. In
addition, the possible biological and clinical significance of
PSTI expression in colorectal cancer is also discussed.
Materials and methods
Tissue preparation
The tissues were supplied from surgical specimens resected at
the 2nd Dept of Surgery, Osaka University Hospital. They
were immediately fixed in 10% cold buffered formalin saline
for immunohistochemistry and in situ hybridisation, then
embedded in paraffin.
For Northern blot hybridisation, tumour tissues and nor-
mal colonic mucosa, taken from a region distant from the
edge of the tumour tissue, were immediately frozen and
stored in liquid nitrogen.
Correspondence: M. Higashiyama, Department of Surgery, The
Center for Adult Diseases, Osaka, 3 Nakamachi 1-chome,
Higashinari-ku, Osaka 537, Japan.
Received 19 April 1990; and in revised form 28 June 1990.
Preparation ofanti-PSTI antiserum and immunohistochemical
study
Anti-PSTI antiserum used in this study was produced in
rabbits as previously described (Kitahara et al., 1980). Its
sensitivity and specificity were also confirmed by radioim-
munoassay.
Immunohistochemical study was performed according to a
modified method of Hsu et al. (1981). Briefly, sections were
dewaxed in xylene, rehydrated with a series of ethanol solu-
tions, and endogenous peroxidase activity was blocked using
0.3% hydrogen peroxide in methanol for 30 min. After
immersion in 3% normal goat serum for 30 min, in order to
block non-specific binding, the sections were incubated with
primary anti-PSTI antiserum at a dilution of 1:400 overnight
at 4°C, and subsequently with biotinylated goat anti-rabbit
IgG (Vector) and avidin-biotin peroxidase complex (Vecta-
stain ABC kit, Vector) for 30 min each at room temperature.
They were washed in PBS between each incubation step. The
peroxidase reaction was applied using 0.02% 3,3'-diamino-
benzidine tetrahydrochloride (Sigma; St Louis, MO, USA) in
0.05 M Tris-HCI (pH 7.6) containing 0.01% hydrogen perox-
ide, producing a brown stain in areas of antibody binding.
Negative controls, in which normal rabbit serum was used,
were included for each case. As positive controls, PSTI
positive specimens from normal pancreas were simul-
taneously stained.
The degree of PSTI immunoreactivity was semiquantit-
atively assessed for staining intensity as the percentage of
PSTI-positive cancerous cells, more than 30%, (+ +,
strongly positive); less than 30%, (+, weakly positive); and
0%, (-, negative).
Preparation ofPSTI cDNA probe and in situ hybridisation
study
A 378 bp fragment of ATIC-I, which covers a 237-nucleotide
amino acid coding region, a 60-nucleotide 5'-non-coding
region and a 81-nucleotide 3'-non-coding region, was used as
a probe (Tomita et al., 1987). A 585 bp Sau 3A I fragment of
pUC 19 vector DNA was used as a negative control probe.
Sulphonation of DNA probes for in situ hybridisation was
performed by treating denatured DNA with a mixture of
bisulphite and o-methylhydroxylamine (Budowsky et al.,
1972).
The procedure used for in situ hybridisation is a
modification of that which has been reported previously
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(Morimoto et al., 1987). Briefly, the sections were dewaxed,
rehydrated, and endogenous peroxidase activity was blocked
in absolute methanol with 1% hydrogen peroxidase. They
were then treated with 0.2 N HCI, heated to 65°C in 2 x SSC
(1 x SSC = 0.15 M sodium chloride, 0.015 M tri-sodium cit-
rate, pH 7.0), and digested with proteinase K (5 pg ml-') for
5 min at 37°C. After acetylation with 0.25% glacial acetic
acid in 0.1 M triethanolamine buffer for 20min, they were
prehybridised for 4 h at 42°C. Hybridisation was performed
for 12-18 h at 42°C, using a 0.4 ng Al1- sulphonated PSTI or
pUCl9 cDNA probe. The unhybridised probe was
thoroughly washed off in 2 x SSC at 37°C for 4-6 h, and
finally washed in 0.1 x SSC for 30 min.
The detection of hybrids was performed by the same
immunohistochemical method as that for PSTI, using 3%
normal horse serum to block non-specific binding, anti-
sulphonated DNA antibody (Orgenics, Yavne, Israel) as
primary antibody, and biotinylated horse anti-mouse IgG as
secondary antibody. The procedure after the avidin-biotin
peroxidase complex reaction was the same as mentioned
above. Normal human pancreatic tissue was used as positive
controls for the detection of PSTI mRNA.
Northern blot hybridisation
Total cellular RNA was isolated from the tissues of colorec-
tal cancer and normal colon mucosa, as described by Chirg-
win et al. (1979). mRNA was purified from total RNA by
repeated passage through a type 7 oligo (dT) cellulose col-
umn (Pharmacia, Sweden). An aliquot (5 gAg) of mRNA was
denatured by heating at 65°C for 15 min in 50% formamide,
electrophoresed in a 1% agarose/2.2 M formaldehyde gel as
described by Lehrach et al. (1977) and then transferred to a
nylon filter (Gene Screen Plus, NEN, USA). After prehy-
bridisation at 65°C for several hours, hybridisation with a
32P-labelled PSTI cDNA probe (1-2 x 106 c.p.m. ml ') was
performed at 65°C for 12-18 h. After the filter was washed
in 2 x SSC at 650C for 30 min and then rinsed in 0.1 x SSC
at room temperature, it was exposed to X-ray film (Kodak
XA-5) for 5 days at - 700C. As positive control, normal
human pancreatic tissue (0.1 gg of mRNA) was also applied.
Statistical analysis
Statistical comparison was evaluated using the X2 test;
P <0.05 was considered to be significantly different.
Results
Immunohistochemistry on PSTI
Of the 95 colorectal cancer cases examined, 80 cases (84%)
stained positively with varying degrees of immunoreactivity:
18 cases stained weakly, and 62 cases strongly (Figure 1).
The relationship between PSTI expression and histological
type is shown in Table I. The incidence of PSTI expression in
well or moderately differentiated adenocarcinomas was
greater than in the other types.
Table II shows the relationship between PSTI expression
and clinicopathological analyses with regard to stage, tumour
size, depth of invasion, nodal involvement and liver meta-
stasis. There were no obvious differences in the incidence of
PSTI expression among stages, nodal involvement and liver
metastasis. However, as tumour size enlarged, PSTI was
expressed more frequently and more strongly (P <0.01).
Moreover, in cases which showed strong PSTI immunoreac-
tivity, the incidence of PSTI expression gradually increased
with the depth of tumour invasion: cases with invasion into
the submucosal layer, into the intramuscular layer, within the
serosal layer or adventitia, and into the surrounding organs
showed incidences of 30, 67, 69 and 78%, respectively. In
particular, the incidence of cases invading within the serosal
layer was significantly higher than that of cases only invading
the submucosal layer (P <0.05).
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Figure 1 Immunohistochemical staining of PSTI in colorectal
cancer. Mayer's haematoxylin counter stain. a, Well differentiated
adenocarcinoma expressing PSTI weakly as indicated by arrows
(original magnification x 40). b, Well differentiated adenocar-
cinoma showing strong reactivity with the anti-PSTI antiserum
(original magnification x 33).
Table I The relationship between PSTI expression and histological
type in colorectal cancer
PSTI expression
Histology - + + + Incidence (%)
Well-mod 8 16 60 76/84 (90)
Poor 4 1 1 2/6 (33)
Muc 2 1 1 2/4 (50)
Sig 1 0 0 0/1 (0)
Total 15 18 62 80/95 (84)
aWell-mod: well or moderately differentiated adenocarcinoma.
Poor: poorly differentiated adenocarcinoma. Muc: mucinous
carcinoma. Sig: signet ring cell carcinoma.
Detection on PSTI mRNA
Of the 15 colorectal cancer cases tested, transcripts were
detected in 9 cases by in situ hybridisation analysis, and in 13
cases by Northern blot hybridisation analysis (Table III).
Using the in situ hybridisation method, PSTI mRNAs were
detected in colorectal cancerous cells (Figure 2a), while no
staining was detected by negative probe (Figure 2b). As
positive control, PSTI mRNAs were demonstrated in the
acini of the normal pancreas (Figure 2c).
Representative Northern blot hybridisations are also
shown in Figure 3. A hybridising band of about 530
nucleotides was detected with varying degrees of density in
each lane: 2 (case no. 13), 3 (case no. 5), 4 (case no. 1) and 5
(case no. 6). Lane 6 (case no. 4) was negative for PSTI
mRNA. In lane 1, normal pancreatic mRNA was used as a
positive control.956 M. HIGASHIYAMA et al
Table II The relationship between PSTI expression and
clinicopathological analyses in colorectal cancer
PSTI expression
- + + + Incidence (%)
stagea
A 5 (26) 4 (21) 10 (53) 14/19 (74)
B 1 (4) 5 (19) 21 (78) 26/27 (96)
C 5 (19) 3 (12) 18 (69) 21/26 (81)
D 4 (17) 6 (26) 13 (57) 19/23 (83)
Tumour size (cm)b
T<4 2 (10) 9 (45) 9 (45) 18/20 (90)
4 T<8 13 (20) 8 (12) 45 (68) 53/66 (80)
8 T 0 (0) 1 (11) 8 (89) 9/9 (100)
Depth of invasion
Submucosal layer 3 ((30) 4 (40) 3 (30)C 7/10 (70)
Intramuscular layer 4 (33) 0 (0) 8 (67) 8/12 (67)
Serosal layer or 7 (11) 13 (20) 44 (69)c 57/64 (89)
adventitia
Surrounding organs 1 (11) 1 (11) 7 (78) 8/9 (89)
Nodal involvement
Negative 9 (18) 10 (20) 31 (62) 41/50 (82)
Positive 6 (13) 8 (18) 31 (69) 39/45 (87)
Liver metastasis
Negative 12 (16) 12 (16) 51 (68) 63/75 (84)
Positive 3 (15) 6 (30) 11 (55) 17/20 (85)
aAccording to the criteria of Dukes' staging. bSignificantly
different (P <0.01). cSignificantly different (P <0.05).
Table III Detection of PSTI and its mRNA in colorectal cancer
Size PSTI
No. Age Sex Hist. Stage (cm) Dep. IH ISH North
01 54 m well A 3.4 im ++ + +
02 54 f poor A 7.5 im - - +
03 60 m mod B 3.8 s + - +
04 87 m mod B 4.0 s - - -
05 69 m mod D 4.2 s ++ - +
06 61 m mod B 4.5 s ++ - +
07 55 f well D 4.5 s ++ + +
08 56 m well B 4.7 s ++ + +
09 56 m well C 5.5 s ++ + +
10 50 m mod B 7.0 s ++ + +
11 45 f well B 7.0 s
12 49 m mod C 7.0 s ++ + +
13 34 m well B 8.5 s ++ + +
14 62 f mod B 8.5 s ++ + +
15 46 m mod B 11.0 s ++ + +
12/15 9/15 13/15
(80%) (60% (87%)
Hist.: histology, reference to Table I. Stage: Dukes' staging. Dep.:
depth of invasion. im: invasion into the intramuscular layer.
s: invasion within the serosal layer or adventitia. IH: immuno-
histochemistry. ISH: in situ hybridisation. North: Northern blot
hybridisation.
Discussion
Several studies have now examined the expression of PSTI in
various neoplasms (Higashiyama et al., 1990; Ogata, 1988;
Ogawa et al., 1987; Tomita et al., 1987; Ueda et al., 1989).
The presence of PSTI in gynaecological cancer and gastric
cancer was immunohistochemically demonstrated using the
same anti-PSTI antiserum used in this study (Higashiyama et
al., 1990; Ueda et al., 1989). Using biochemical assays, it was
also reported that a pancreatic cancer cell line, CAPAN-1,
produces PSTI (Ogata, 1988). When a PSTI cDNA clone has
been isolated and sequenced, the expression of PSTI at the
gene level can be examined. In fact, it was shown that the
transcript of PSTI could be detected in some lung cancer
tissues by Northern blot hybridisation analysis (Tomita et al.,
1987). However, the expression of PSTI in neoplasms has not
been simultaneously examined at both the product and the
a
b
Figure 2 Moderately differentiated adenocarcinoma strongly
showing PSTI mRNA. Mayer's haematoxylin counter stain
(original magnification x 100). a, In situ hybridisation with PSTI
cDNA probe. b, In situ hybridisation with pUC19 probe as a
negative control. c, Normal human pancreatic tissues showing
strong reactivity on in situ hybridisation with PSTI cDNA probe
as a positive control. Note the absence of staining in islet cells
and pancreatic duct cells (I, islet cells; D, pancreatic duct cells,
original magnification x 133).
transcriptional level. Besides, by Northern blot hybridisation
analysis, although the method is now reliably established,
only total admixtures of mRNA, not only from cancerous
cells but from stromal cells and/or occasionally non-
cancerous epithelial cells in the tissues, can be evaluated. In
this respect, the present study appears to be of much value,
as the evidence that PSTI is produced and expressed by
cancerous cells in colorectal cancerous tissues can be convinc-
ingly demonstrated only by simultaneous in situ detection
of PSTI and PSTI mRNA in addition to Northern blot
hybridisation analysis.
While the expression of PSTI was observed in 90% of well
or moderately differentiated adenocarcinomas, histologically
common types of colorectal cancer, it was observed that the
incidence of PSTI expression in histologically uncommon
types including poorly differentiated adenocarcinomas,
mucinous carcinomas and signet ring cell carcinomas wasPSTI IN COLORECTAL CANCER 957
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Figure 3 Northern blot hybridisation with PSTI cDNA (lane 1,
normal pancreas; lane 2, case no. 13; lane 3, case no. 5; lane 4,
case no. 1; lane 5, case no. 6; lane 6, case no. 4).
low, although the number of cases examined was small. In
contrast, it has been previously shown that in gastric cancer,
poorly differentiated adenocarcinomas or signet ring cell car-
cinomas contained PSTI at a rather high incidence
(Higashiyama et al., 1990). Therefore, the possibility may
exist that the expression of PSTI in cancerous cells is highly
variable among the organs and/or tissues of primary origin,
irrespective of histological differentiation or mucin produc-
tion.
The biological and clinical significance of PSTI expression
in colorectal cancer, although still unknown, is of much
interest. Two possibilities may be considered to explain its
significance. Firstly, PSTI may act as a proteinase inhibitor
against proteolytic enzyme systems, like the trypsin-PSTI
system in the pancreas. Tumour invasion is now associated
with local production of some proteolytic enzymes by tumor-
ous cells (Tryggvason etal., 1987). Besides, in tumour tissues,
such a proteolytic enzyme and its inhibitor occur together,
and the latter could be involved in the inhibition of the
former enzymatic activity (Kataoka et al., 1989; Strauli et al.,
1980; Turpeinen et al., 1988). Tumour-associated trypsin
inhibitor, TATI, is a peptide identified in ovarian cancerous
extracts, the N-terminal amino acid sequence of which is very
similar to PSTI (Halila et al., 1987). The ability of TATI to
inhibit not only trypsin but also some fibrinolytic enzymes,
such as plasmin, urokinase, and tissue-type plasminogen
activator, has been recently demonstrated in its physiological
concentrations, suggesting that TATI has a possible role in
proteolytic control involving these proteinases (Turpeinen et
al., 1988). However, there is no evidence that colorectal
cancer may produce trypsin, and the reaction between PSTI
and these fibrinolytic enzymes is yet to be resolved, although
fibrinolytic enzyme activities have recently been observed in
colorectal cancerous tissues (Kohga et al., 1985).
Secondly, although conclusive evidence has not yet been
obtained, it has been suggested that PSTI itself may be a
growth factor-like substance (Niinobu et al., 1986; Ogawa et
al., 1987). PSTI can stimulate DNA synthesis in human
fibroblasts in vitro (Ogawa et al., 1985), and rat
cholecystokinin-releasing peptide (CCK-RP), which may be
identical to rat PSTI, has been shown to stimulate the growth
of 3T3 fibroblasts (Fukuoka et al., 1986). In fact, we recently
reported that a strongly positive PSTI-immunoreactivity was
detected in the scirrhous type ofgastric cancer (Higashiyama
et al., 1990). Moreover, McKeehan et al. (1986) showed that
tumour-associated proteinase inhibitor, ECGF-2a, isolated
from human hepatoma cells, the first 25 amino acids of the
N-terminal sequence of which is identical to PSTI, may
possess a function as endothelial cell growth factor. On the
other hand, primary amino acid sequence similarities between
PSTI and epidermal growth factor (EGF) have been previ-
ously demonstrated (Hunt et al., 1974; Sheving, 1983), and
the nucleotide sequences of human PSTI mRNA and mouse
EGF mRNA have been shown to be highly homologous
(Yamamoto et al., 1985). Besides, the binding site for PSTI
has been found in various cultured cells, which is distinct
from the receptor for EGF (Niinobu et al., 1986). Further-
more, it has been also suggested that PSTI may have an
effect on fetal pancreatic development (Fukayama et al.,
1986). These findings raise the possibility that PSTI may
possess a growth-stimulating function on stromal cells in the
neoplastic tissues as well as neoplastic cells. Therefore, it can
be speculated that PSTI produced by tumorous cells acts as
an 'active' or 'positive' growth-stimulating factor on the
development of tumour tissues, rather than in a 'passive' role
only like proteinase inhibitor.
Recently, it has been reported that alpha-l-antitrypsin, a
trypsin inhibitor, is more frequently expressed in advanced
cases of colorectal cancer than in early ones, indicating that
it may be a useful biological marker for prognosis ofcolorec-
tal cancer (Karashima et al., 1990). The role and significance
ofalpha-l-antitrypsin expression in colorectal cancer has also
been unknown, but it is speculated that it may act as an
endothelial cell growth factor or a modulator of host-
tumour immune response in cancerous tissues (Ades et al.,
1982; McKeehan et al., 1986). The present observations that
the increased incidence of immunohistochemically strong
reactivity for PSTI correlated well with depth ofinvasion and
tumour size may resemble in some respects similar observa-
tions for alpha-l-antitrypsin. Thus, like alpha-l-antitrypsin,
the expression of PSTI in colorectal cancer may possibly be
associated with tumour development. However, this
immunohistochemical finding was not confirmed by the
transcriptional level of PSTI because of the small number
measured.
In conclusion, it was observed that PSTI is commonly
produced and expressed in colorectal cancer. Moreover, we
have discussed the possible biological and clinical significance
of PSTI in colorectal cancerous cells, and the immunohisto-
chemical findings that more advanced cases, with regard to
tumour size and depth of invasion, may express more PSTI.
These data suggest that PSTI may play a role in colorectal
cancer which is closely associated with tumour development.
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